Neoadjuvant concurrent or sequential anthracycline-containing chemotherapy and HER2-targeted agents for HER2-positive breast cancer: a randomized phase 2 study (METIS)

The integration of anthracyclines with HER2-targeted agents in neoadjuvant therapy for HER2-positive breast cancer has been limited by cardiotoxicity concerns.

By Zheng, Wang, Wu +22Signal transduction and targeted therapyNov 2, 2026

Score█████░░░░░5.2

Key numbers

67.5% vs
95% confidence interval
58.7% vs

VerdictA leading story on any desk.

Read the original PDF

Abstract

The integration of anthracyclines with HER2-targeted agents in neoadjuvant therapy for HER2-positive breast cancer has been limited by cardiotoxicity concerns. This randomized phase II METIS trial (NCT04172259) assessed whether concurrent pegylated liposomal doxorubicin (PLD)-containing chemotherapy plus dual HER2 blockade (trastuzumab/pertuzumab) could improve efficacy without increasing cardiac risk. A total of 156 patients with stage II-III HER2-positive breast cancer were randomized to a PLD-based concurrent regimen or an epirubicin and cyclophosphamide (EC)-based sequential regimen. The PLD-based concurrent group achieved a higher pathological complete response (pCR) rate (67.5% vs. 48.7%; difference, 18.8%; 95% confidence interval [CI], 3.6-34.0; P = 0.033) compared with the EC-based sequential group, with greater benefit in hormone receptor-positive disease (58.7% vs. 36.7%) and stage II tumors (82.1% vs. 48.0%). After a median follow-up of 37.5 months, fewer event-free survival (EFS) events occurred in the PLD-based concurrent group (3 vs. 8), yielding a hazard ratio (HR) of 0.35 (95% CI, 0.09-1.32; P = 0.105). The estimated 3-year EFS rates were 96.0% (95% CI, 88.1-98.7) versus 90.7% (95% CI, 81.5-95.6). Achieving pCR was significantly associated with improved EFS (HR = 0.15; 95% CI, 0.03-0.71; P = 0.006). Cardiac safety was comparable, with no symptomatic cardiac dysfunction and only one grade ≥3 cardiotoxicity in the EC-based sequential group. These findings support PLD-based concurrent therapy with trastuzumab and pertuzumab as an effective and safe neoadjuvant option for high-risk HER2-positive breast cancer, warranting further evaluation in phase III trials.

Qiufan Zheng, Shusen Wang, Zhiyong Wu, Muyi Zhong, Fei Xu, Shihui Ma, Yuanqi Zhang, Lehong Zhang, Yanxia Shi, Ying Wang, Heng Huang, Xiaopeng Ma, Xiangdong Xu, Haiyan Li, Jibin Li, Xiwen Bi, Jiajia Huang, Kuikui Jiang, Xin An, Ruoxi Hong, Meiting Chen, Cong Xue, Yongyi Zhong, Zhongyu Yuan, Wen Xia

The editor's rubric

Heuristic review

Leverage2 / 5: Reusable within one subfield (a technique, dataset, or protocol a few groups will adopt).; 10% of this desk’s rubric
Magnitude3 / 5: Large gain: roughly 2x, or a clear new state of the art on a hard, unsaturated problem.; 20% of this desk’s rubric
Evidence5 / 5: Definitive: phase 3 randomized evidence on hard endpoints, multi-lab replication, or community verification at scale.; 32% of this desk’s rubric
Novelty2 / 5: A new combination of known ideas.; 8% of this desk’s rubric
Trajectory2 / 5: Some room to improve with obvious engineering.; 5% of this desk’s rubric
Stakes3 / 5: Meaningful benefit to many people within a few years.; 25% of this desk’s rubric

Dimension	Level	Weight	What that level means
Leverage	██░░░2/5	10%	Reusable within one subfield (a technique, dataset, or protocol a few groups will adopt).
Magnitude	███░░3/5	20%	Large gain: roughly 2x, or a clear new state of the art on a hard, unsaturated problem.
Evidence	█████5/5	32%	Definitive: phase 3 randomized evidence on hard endpoints, multi-lab replication, or community verification at scale.
Novelty	██░░░2/5	8%	A new combination of known ideas.
Trajectory	██░░░2/5	5%	Some room to improve with obvious engineering.
Stakes	███░░3/5	25%	Meaningful benefit to many people within a few years.

Editor’s rationale

Heuristic triage from title and abstract text only, not a reading of the paper. Cues found: gains (versus baseline, efficacy); design (randomized, phase 3, registered); verification (confidence interval, p-value); stakes (mortality, major disease, prevention or cure).

How the score was computed

rank-2026-10-18

Score█████░░░░░5.2

Score = 10 × (80% × adjusted merit / 10 + 10% × attention + 10% × freshness)

Desks place stronger verdicts first, then use this score to order work within the same verdict.

Merit: 6.8 / 10; Weighted rubric, evidence-gated.
Adjusted merit: 5.4 / 10; Shrunk toward the desk prior by editor confidence (50%).
Attention: 0%; Citations, upvotes, points, mentions.
Freshness: 85%; Half-life decay since publication.

Citations0 (reference 20, via openalex, Nov 4, 2026, 06:17 UTC)

The record

Reviewed by heuristic-v10 on Nov 4, 2026, 06:17 UTC. Paper type: clinical.
Categories: Clinical Trial, Phase II, research-article, Randomized Controlled Trial, Journal Article, Humans, Breast Neoplasms, Polyethylene Glycols, Cyclophosphamide, Anthracyclines, Doxorubicin
TOP, No.5 in the Medicine edition of November 4, 2026.